Natixis Advisors LLC Makes New $327,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Key Points

• Natixis Advisors LLC has invested approximately $327,000 in Pacira BioSciences by acquiring 13,139 shares in the company during the first quarter.
• Analysts have recently upgraded Pacira BioSciences from a "hold" to a "buy" rating, with a consensus target price of $30.83 per share.
• Despite recent investments and positive earnings reports, Pacira BioSciences stock has experienced a 1.5% decline recently, with shares opening at $24.81.

Natixis Advisors LLC bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 13,139 shares of the company's stock, valued at approximately $327,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new stake in shares of Pacira BioSciences in the first quarter valued at about $277,000. ProShare Advisors LLC lifted its position in Pacira BioSciences by 30.2% in the 4th quarter. ProShare Advisors LLC now owns 16,003 shares of the company's stock worth $301,000 after buying an additional 3,710 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Pacira BioSciences by 112.8% during the first quarter. GAMMA Investing LLC now owns 3,694 shares of the company's stock valued at $92,000 after buying an additional 1,958 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Pacira BioSciences by 3.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company's stock worth $491,000 after acquiring an additional 794 shares during the last quarter. Finally, LPL Financial LLC bought a new position in shares of Pacira BioSciences during the fourth quarter valued at $251,000. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Stock Performance

Shares of PCRX traded down $0.21 during midday trading on Friday, reaching $24.78. The stock had a trading volume of 986,681 shares, compared to its average volume of 810,302. Pacira BioSciences, Inc. has a one year low of $12.61 and a one year high of $27.64. The company has a current ratio of 2.38, a quick ratio of 1.91 and a debt-to-equity ratio of 0.50. The firm has a 50 day simple moving average of $23.46 and a 200-day simple moving average of $24.62. The firm has a market cap of $1.11 billion, a PE ratio of -8.91 and a beta of 0.48.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.01. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The firm had revenue of $181.10 million for the quarter, compared to the consensus estimate of $183.11 million. During the same quarter in the prior year, the company posted $0.96 earnings per share. The business's revenue was up 1.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Pacira BioSciences, Inc. will post 2.41 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on PCRX shares. Needham & Company LLC cut their price target on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a report on Friday, May 9th. Truist Financial raised Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 target price for the company in a research note on Friday, July 25th. Finally, Wall Street Zen raised Pacira BioSciences from a "hold" rating to a "buy" rating in a report on Friday, June 6th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.83.

Insider Activity

In related news, Director Marcelo Bigal sold 4,912 shares of the firm's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $23.67, for a total value of $116,267.04. Following the completion of the sale, the director directly owned 11,393 shares in the company, valued at $269,672.31. This trade represents a 30.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Lauren Riker sold 5,578 shares of the business's stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total value of $146,199.38. Following the sale, the senior vice president owned 59,564 shares in the company, valued at $1,561,172.44. The trade was a 8.56% decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.